Rockwell Medical

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rockwell Medical reports record revenue and eyes global expansion

Rockwell Medical's Q4 2022 earnings call showcased strong revenue growth, operational improvements, and strategic initiatives for future profitability. While challenges in expense optimization and debt reduction persist, the company's focus on growth through international partnerships and new product developments presents promising opportunities. Overall, Rockwell Medical is on track to achieve financial stability and sustained growth in the healthcare market.

Rockwell Medical reports record revenue and progress towards profitability

Rockwell Medical (RMTI) delivered strong Q1 2023 results with record revenue and progress towards profitability. The company's strategic initiatives, including the successful transition of the Baxter business, are driving growth. Despite challenges, Rockwell Medical's focus on cost reduction and business development positions it well for future success.

Rockwell Medical reports Q2 challenges but eyes profitability in 2024

Rockwell Medical's Q2 2023 performance reflects challenges in net sales and profitability but highlights strategic progress towards financial stability and growth.
The company's strengths lie in revenue increase, expense reduction, and the acquisition of Evoqua's business, positioning it for accelerated profitability.
While facing challenges in financial results and product development, Rockwell's focus on market expansion and optimization presents opportunities for future growth and revenue diversification.

Rockwell Medical posts record Q3 sales, eyes profitability in Q4

Rockwell Medical's Q3 performance reflects strong sales growth and strategic acquisitions.
While facing margin challenges, the company's focus on profitability and leadership enhancements bode well.
Opportunities lie in market dominance, operational improvements, and leveraging customer agreements.
Maintaining financial stability and pursuing growth avenues are key priorities for Rockwell's future success.

Rockwell Medical achieves historic profitability and projects strong sales growth

Rockwell Medical's Q4 2023 performance reflects significant milestones with profitability achieved and record net sales reported. The company's strategic focus on operational efficiency, growth projections, and margin improvements indicate a positive trajectory. While challenges persist, Rockwell is well-positioned to leverage opportunities for sustained growth and profitability.

Rockwell Medical reports record Q1 sales and profitability growth

Rockwell Medical delivered robust financial results in Q1 2024, showcasing growth in net sales, gross profit, and improved profitability metrics.
The company's strategic initiatives to enhance margins, optimize operations, and reduce debt position it well for future growth and value creation.
While facing challenges in a competitive market, Rockwell's unique market position and financial discipline provide a solid foundation for sustained success.

Rockwell Medical reports record-high sales and profitability, eyes global expansion

Rockwell Medical's Q3 2024 performance reflects strong financial health, profitability, and record-high sales, underpinned by strategic initiatives and partnerships.
The company faces challenges in customer dynamics but is well-positioned to capitalize on growth opportunities in at-home dialysis and international markets.
With a focus on quality, customer service, and sustainable profitability, Rockwell Medical is poised for continued success and market expansion.
Overall, Rockwell Medical's Q3 2024 earnings call highlights resilience, adaptability, and a positive outlook for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in 1996 and is headquartered in Wixom, MI.

Rockwell Medical's (RMTI) CEO Russell Ellison on Q1 2021 Results - Earnings Call Transcript

Shares of Rockwell Medical (NASDAQ:RMTI) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 33.33% year over year to ($0.08), which beat the estimate of ($0.09).

Recap: Rockwell Medical Q1 Earnings

-Home Infusion FPC Program expected to initiate Phase 2 trial in second half of 2021-

Rockwell Medical, Inc. Provides First Quarter 2021 Financial and Operational Update

Rockwell Medical (RMTI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Rockwell Medical (RMTI)

WIXOM, Mich., April 22, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it presented data from a clinical feasibility study reviewing the practice patterns of iron deficiency anemia (IDA) in home parenteral nutrition patients at the National Home Infusion Association's (NHIA) 2021 Annual Conference, taking place virtually from April 19 to 22, 2021.

Rockwell Medical Presents Data on Diagnosis and Management of Iron Deficiency Anemia in Home Parenteral Nutrition Patients at the NHIA 2021 Annual Conference

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q4 2020 Results - Earnings Call Transcript

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -12.50% and -5.34%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Rockwell Medical (RMTI) Reports Q4 Loss, Lags Revenue Estimates

Shares of Rockwell Medical (NASDAQ:RMTI) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 18.18% year over year to ($0.09), which missed the estimate of ($0.08).

Rockwell Medical: Q4 Earnings Insights

Rockwell Medical, Inc. Provides Fourth Quarter and Full Year 2020 Financial and Operational Update

On Wednesday, March 31, Rockwell Medical (NASDAQ:RMTI) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

Rockwell Medical's Earnings: A Preview

Investors need to pay close attention to Rockwell Medical (RMTI) stock based on the movements in the options market lately.

Do Options Traders Know Something About Rockwell Medical (RMTI) Stock We Don't?

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Rockwell Medical (RMTI) Report Negative Q4 Earnings? What You Should Know

WIXOM, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that Triferic AVNU (ferric pyrophosphate citrate injection), the intravenous (IV) formulation of Triferic, is now available to patients in the United States. Triferic AVNU was approved by the U.S. Food and Drug Administration (FDA) in March 2020 and is indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).

Rockwell Medical Announces U.S. Availability of Triferic® AVNU for Replacement of Iron and Maintenance of Hemoglobin in Patients on Hemodialysis

>82,000 patients receiving hemodialysis annually >82,000 patients receiving hemodialysis annually

Rockwell Medical Announces Submission of Triferic® New Drug Application in South Korea by Partner, Jeil Pharmaceutical Co., Ltd.

Rockwell Medical (RMTI) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Rockwell Medical (RMTI) Looks Good: Stock Adds 5.9% in Session

China is a sizable and growing market, with more than 600,000 patients receiving hemodialysis annually China is a sizable and growing market, with more than 600,000 patients receiving hemodialysis annually

Rockwell Medical Announces Dosing of First Patient in Pivotal Triferic® Phase 3 Trial by Partner, Wanbang Biopharmaceuticals, in China

WIXOM, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today announced the Rockwell Medical executive management team will record a presentation at H.C. Wainwright BioConnect 2021 Conference. This presentation will become publicly available on January 11, 2021, at 6:00 a.m. ET and will be archived for 30 days thereafter, via the Company's website at www.rockwellmed.com, under the “Investors” section.

Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2021 Conference

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q3 2020 Results - Earnings Call Transcript

Rockwell Medical, Inc. (RMTI) CEO Russell Ellison on Q2 2020 Results - Quick Version Earnings Call Transcript

- Ended the quarter with $67.3 million in cash, cash equivalents and investments-

Rockwell Medical, Inc. Provides Third Quarter 2020 Financial and Operational Update

WIXOM, Mich., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, November 9, 2020, at 4:30 p.m. ET to discuss its financial results for the three months ended September 30, 2020, and recent operational highlights.

Rockwell Medical to Report Third Quarter 2020 Financial and Operating Results on November 9, 2020

WIXOM, Mich., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that two abstracts have been accepted for poster presentation at the American Society of Nephrology (ASN) Virtual Kidney Week 2020, which will occur from October 20 to 25, 2020.

Rockwell Medical, Inc. Announces Presentations at the American Society of Nephrology Virtual Kidney Week 2020

-New indications for FPC platform provide significant  growth  opportunity-

Rockwell Medical Announces Growth Plan and New Therapeutic Opportunities for Its Ferric Pyrophosphate Citrate (FPC) Platform

WIXOM, Mich., Sept.  23, 2020  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has entered into securities purchase agreements with several healthcare-focused and other institutional investors to purchase 23,178,809 of its shares of common stock (or common stock equivalents in lieu thereof) and short-term warrants to purchase up to an aggregate of 23,178,809 shares of common stock, in a registered direct offering priced at-the-market under Nasdaq rules.  The combined purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock is $1.51. The warrants have an exercise price of $1.80 per share, will be immediately exercisable, and will expire 24 months from the issue date.

Rockwell Medical Announces $35.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Rockwell Medical (RMTI) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

News for Rockwell Medical Stock (RMTI)